MCF7 cells depleted of PRMT1 or BRCA1 showed a significant decrease in Bcl-2 protein, but experiments in the presence of MG132 (Fig. 6C), a proteasome inhibitor, and analysis of Bcl-2-mRNA (Fig. 6C) indicated that BRCA1 and PRMT1 might differentially regulate Bcl-2 protein levels in breast cancer cells. This evidence concerns the gene PRMT1 and breast cancer.